



## Myriad Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

SALT LAKE CITY, May 26, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the treatment of cancer and HIV infection, today announced that Adrian N. Hobden, President and CEO of Myriad Pharmaceuticals, will provide an overview of the Company at the following conferences:

- The 9<sup>th</sup> Annual Needham Healthcare Conference on June 10, 2010 at 8:40 a.m. ET at The New York Palace Hotel in New York City.
- The Jefferies 2010 Global Life Sciences Conference on June 11, 2010 at 10:30 a.m. ET in New York City.

The Needham Healthcare Conference presentation will be available via live audio webcast on the Company's website at [www.myriadpharma.com](http://www.myriadpharma.com). Archived replays will also be located on the Company's site following the event.

### About Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics. For more information visit [www.myriadpharma.com](http://www.myriadpharma.com).

The Myriad Pharmaceuticals, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

### Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled presentation of an overview of the Company at the 9th Annual Needham Healthcare Conference on June 10, 2010, and the Jefferies 2010 Global Life Sciences Conference on June 11, 2010. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable to develop and maintain manufacturing capabilities for our products; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in our in our Form 10-K, for the year ended June 30, 2009, which was filed with the Securities and Exchange Commission on September 28, 2009, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad Pharmaceuticals undertakes no duty to update this information unless required by law.

CONTACT: Myriad Pharmaceuticals, Inc.  
Patrick M. Burke, Ph.D., V.P. Corporate  
and Business Development  
801-214-7822  
[investor.relations@myriadpharma.com](mailto:investor.relations@myriadpharma.com)

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.